About Afimmune

Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on new medicines to improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. Afimmune has assets in various stages of clinical and pre-clinical development. Afimmune pipeline

Latest News

March 29, 2017

Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis

Dublin, Ireland, 29th March 2017: Afimmune, a privately held biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted fast track […]
September 6, 2016

Afimmune Will Present Data on Oral DS102 at the European Respiratory Society

Dublin, Ireland, 6th September 2016: Afimmune will today present an abstract entitled ”DS102: a bioactive lipid for the treatment of chronic pulmonary disorders” at the European […]

Join our mailing list

Contact us

t: +353 1 2946380 e: info@afimmune.com